-
Navitoclax (previously ABT-263) is an
experimental orally active anti-cancer drug,
which is a Bcl-2
inhibitor similar in
action to obatoclax. Navitoclax...
-
appropriate for
clinical trials,
while its
orally bioavailable derivative navitoclax (ABT-263) has
similar activity on
small cell lung
cancer (SCLC) cell lines...
-
development of
navitoclax (ABT-263) as an orally-available
derivative with
similar activity on
small cell lung
cancer (SCLC) cell lines.
Navitoclax entered clinical...
- the
chemotherapeutic drug
dasatinib and the
experimental small molecule navitoclax.
Soluble urokinase plasminogen activator surface receptor have been found...
-
inhibitors (e.g. FDA
approved venetoclax,
obatoclax in
clinical trials,
navitoclax, and gossypol. PARP
inhibitors (e.g. FDA
approved olaparib, rucaparib...
- (INN)
Natrecor Naturetin Navane naveglitazar (USAN)
Navelbine (GlaxoSmithKline)
navitoclax (USAN)
naxagolide (INN)
naxaprostene (INN)
naxifylline (USAN)...
-
Sotorasib L01XX74
Belzutifan L01XX75
Tebentafusp L01XX77
Adagrasib L01XX78
Navitoclax L01XX79
Eflornithine L01XX80
Imetelstat QL01XX91
Tigilanol tiglate QL01XX92...
- Kirkland,
James L. (2016). "Identification of a
novel senolytic agent,
navitoclax,
targeting the BCL-2
family of anti-apoptotic factors".
Aging Cell. 15...
-
cancer before it had begun,
citing "business decisions" as the reason.
Navitoclax Cephalon Announces Definitive Agreement to
Acquire Gemin X,
March 21,...
- and
defining their role in
apoptosis led to the
development of ABT-263 (
navitoclax) and ABT-199 (venetoclax),
recently FDA-approved for
certain patients...
